CHELMSFORD, Mass., March 17 /PRNewswire/ -- Magellan Biosciences, an emerging leader in systems for clinical-diagnostics, will receive the Frost & Sullivan 2009 North American Product Innovation Award for LeadCare II, a rapid, point-of-care test that enables children and adults to be screened for lead poisoning faster, easier, and more conveniently. Magellan's President of Clinical Diagnostics, James Whelan, will accept the award tomorrow night at the 2009 Excellence in Medical Technologies & Life Sciences Award Banquet in San Francisco, California.
"We are honored to receive this prestigious award, which recognizes both the technical advances required in achieving CLIA-waived status for LeadCare II, and the value of the point-of-care test in meeting a critical healthcare need," said Jim Whelan. "While there has been some encouraging news about U.S. progress in reducing lead poisoning -- this crisis is by no means over. Lead contamination remains a serious problem, and current send-out and prescription-based lead testing practices are missing the children most at risk for lead poisoning. While thankfully they are few and far between, we do get reports of isolated cases, often associated with home reconstruction, where a screening test during a routine check-up identifies a child with seriously high blood-lead levels. We had one as recently as last week. The good news is that in this case, as in all the others, the elevated results triggered an immediate and comprehensive response to attend to the child's health needs and identify and remediate the source of exposure. Unfortunately, despite its proven success in improving health outcomes, across the nation there are still barriers to widespread use of LeadCare II -- from the lack of Medicaid reimbursement to outdated regulations. We continue to work with local, state, and federal officials to ensure that all children have access to the point-of-care test."
|SOURCE Magellan Biosciences|
Copyright©2009 PR Newswire.
All rights reserved